The Oncodetect test is tumor-informed, tracking up to 200 circulating tumor DNA (ctDNA) variants. It delivers simple “detected” or “not detected” results alongside quantitative data to guide adjuvant therapy decisions, monitor treatment response, and detects up to 200 ctDNA variants identifying signs of colorectal cancer recurrence up to two years earlier than imaging.
The commercial launch of Oncodetect, announced 22 April, came in line with Exact Sciences’ previously communicated timeline for a second-quarter 2025 rollout, but notably without securing Medicare coverage.
Key Takeaways
Exact Sciences launched its tumor-informed Oncodetect MRD test for colorectal cancer, but lacks Medicare reimbursement, which limits early commercial potential.
Exact Sciences has officially entered the molecular residual disease (MRD) testing market with the launch of Oncodetect, expanding its precision...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.
SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.
Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.
